{"id":"https://openalex.org/W3085697992","doi":"https://doi.org/10.5414/cp203757","title":"Synergistic effect of bevacizumab and celecoxib on angiogenesis in vitro using human umbilical vein endothelial cells","display_name":"Synergistic effect of bevacizumab and celecoxib on angiogenesis in vitro using human umbilical vein endothelial cells","publication_year":2020,"publication_date":"2020-09-10","ids":{"openalex":"https://openalex.org/W3085697992","doi":"https://doi.org/10.5414/cp203757","mag":"3085697992","pmid":"https://pubmed.ncbi.nlm.nih.gov/32909536"},"language":"en","primary_location":{"id":"doi:10.5414/cp203757","doi":"https://doi.org/10.5414/cp203757","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cp203757","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100682668","display_name":"Abdul S. Qadir","orcid":"https://orcid.org/0000-0002-9133-2558","observed_orcids":["https://orcid.org/0000-0002-9133-2558"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Abdul Qadir","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051951796","display_name":"Mohsin Wahid","orcid":"https://orcid.org/0000-0002-1939-6565","observed_orcids":["https://orcid.org/0000-0002-1939-6565"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mohsin Wahid","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011755508","display_name":"Mahayrookh Asif","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mahayrookh Asif","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5060545417","display_name":"Talat Roome","orcid":"https://orcid.org/0009-0006-7762-0381","observed_orcids":["https://orcid.org/0009-0006-7762-0381"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Talat Roome","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2141,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.38363847,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"58","issue":"12","first_page":"696","last_page":"702"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.002899999963119626,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/celecoxib","display_name":"celecoxib","score":1.0},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.9049999713897705},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.777999997138977},{"id":"https://openalex.org/keywords/human-umbilical-vein-endothelial-cells","display_name":"human umbilical vein endothelial cells","score":0.9729999899864197},{"id":"https://openalex.org/keywords/tube-formation-assay","display_name":"tube formation assay","score":0.7789999842643738},{"id":"https://openalex.org/keywords/endothelial-cell-viability","display_name":"endothelial cell viability","score":0.7279999852180481},{"id":"https://openalex.org/keywords/metastasis","display_name":"metastasis","score":0.5809999704360962},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5450000166893005}],"concepts":[{"id":"https://openalex.org/C2777411675","wikidata":"https://www.wikidata.org/wiki/Q1232438","display_name":"Umbilical vein","level":3,"score":0.9294945001602173},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8236941695213318},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.7742260098457336},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6710176467895508},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.5783114433288574},{"id":"https://openalex.org/C2776467144","wikidata":"https://www.wikidata.org/wiki/Q408801","display_name":"Celecoxib","level":2,"score":0.475710928440094},{"id":"https://openalex.org/C2777834122","wikidata":"https://www.wikidata.org/wiki/Q5939177","display_name":"Human umbilical vein endothelial cell","level":4,"score":0.44348037242889404},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4414829909801483},{"id":"https://openalex.org/C2777663904","wikidata":"https://www.wikidata.org/wiki/Q988343","display_name":"Blood vessel","level":2,"score":0.4175850450992584},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.286787211894989},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.25444382429122925},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21577230095863342},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.19658899307250977},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.10478657484054565}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000068579","descriptor_name":"Celecoxib","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000068579","descriptor_name":"Celecoxib","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002465","descriptor_name":"Cell Movement","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D061307","descriptor_name":"Human Umbilical Vein Endothelial Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.5414/cp203757","doi":"https://doi.org/10.5414/cp203757","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cp203757","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},{"id":"pmid:32909536","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32909536","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4323538967","https://openalex.org/W2409307600","https://openalex.org/W2071998277","https://openalex.org/W2011565456","https://openalex.org/W2145003621","https://openalex.org/W2158728780","https://openalex.org/W2103405384","https://openalex.org/W3037803867","https://openalex.org/W2027359865","https://openalex.org/W165910174"],"abstract_inverted_index":{"OBJECTIVE:":[0],"Angiogenesis":[1],"is":[2,14],"the":[3,22,33,61,94,100,124,170,207,212,229],"underlying":[4],"cause":[5],"of":[6,10,36,96,110,127,172],"a":[7,118,137,176,245],"large":[8],"number":[9],"neoplastic":[11],"diseases.":[12],"It":[13],"necessary":[15],"for":[16,113,156,165],"tumor":[17,23],"metastasis,":[18],"and":[19,38,85,93,99,130,145,163,169,189,201,223,228,242,253],"without":[20],"it":[21],"cannot":[24],"grow":[25],"or":[26],"metastasize.":[27],"This":[28],"study":[29],"aimed":[30],"to":[31,219,233],"determine":[32],"synergistic":[34,246],"effect":[35,247],"bevacizumab":[37],"celecoxib":[39,243],"on":[40,179],"angiogenesis":[41,114,252],"using":[42,67,78,105,117,141,149],"human":[43],"umbilical":[44,62],"vein":[45],"endothelial":[46],"cells":[47],"(HUVEC)":[48],"as":[49],"an":[50],"in":[51,248,250],"vitro":[52,251],"model.":[53],"MATERIALS":[54],"AND":[55],"METHODS:":[56],"HUVEC":[57,71,87,135,180],"were":[58,88,146,210],"isolated":[59],"from":[60],"cord":[63],"by":[64,75,122,187,192,199,204,221,226],"enzymatic":[65],"digestion":[66],"collagenase":[68],"type":[69],"IV.":[70],"characterization":[72],"was":[73,103,115,216,231],"done":[74],"flow":[76,150],"cytometry":[77],"cell":[79,101,157],"surface":[80,158],"markers":[81,159],"CD31,":[82,160],"CD105,":[83,161],"CD146,":[84,162],"CD45.":[86,166],"treated":[89],"with":[90],"bevacizumab,":[91,168],"celecoxib,":[92],"combination":[95,171,255],"both":[97,173],"drugs":[98,174,209],"viability":[102],"assessed":[104],"MTT":[106],"assay.":[107],"The":[108],"formation":[109,120],"capillary-like":[111],"endotubes":[112],"analyzed":[116],"tube":[119,185,197,214],"assay":[121],"measuring":[123],"total":[125,184,196,213],"length":[126,186,198,215],"capillary":[128],"tubes":[129],"branch":[131,190,202,224],"points.":[132],"RESULTS:":[133],"Morphologically,":[134],"showed":[136,153,175],"typical":[138],"cobblestone":[139],"appearance":[140],"inverted-phase":[142],"contrast":[143],"microscopy":[144],"further":[147],"evaluated":[148],"cytometry,":[151],"which":[152],"positive":[154],"expression":[155],"negative":[164],"Celecoxib,":[167],"dose-dependent":[177],"inhibition":[178,259],"viability.":[181],"Celecoxib":[182],"inhibited":[183,195],"15%":[188],"points":[191,203,225],"16.5%.":[193],"Bevacizumab":[194,241],"34%":[200],"49%.":[205],"When":[206],"two":[208],"combined,":[211],"reduced":[217],"due":[218],"synergism":[220],"68%":[222],"80%,":[227],"difference":[230],"found":[232],"be":[234],"statistically":[235],"significant":[236],"(p":[237],"<":[238],"0.001).":[239],"CONCLUSION:":[240],"have":[244],"inhibiting":[249],"their":[254],"achieved":[256],"more":[257],"strong":[258],"than":[260],"either":[261],"drug":[262],"alone.":[263]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-09-21T00:00:00"}